| Print
Coherus BioSciences (CHRS)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Address
333 Twin Dolphin Drive
Suite 600
Redwood City
CA
USA
94065
Telephone
+1 800 7945434
Forecast key dates
| Name | Key Date |
|---|---|
| Coherus BioSciences Inc Annual Report for 2025 | 2026-03-17T00:00:00 |
| Coherus BioSciences Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-10T17:00:00 |
| Coherus BioSciences Inc Fourth Quarter Earnings Results for 2025 | 2026-03-10T00:00:00 |
| Coherus BioSciences Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-06T17:00:00 |
| Coherus BioSciences Inc Third Quarter Earnings Results for 2025 | 2025-11-06T00:00:00 |
| Coherus BioSciences Inc Second Quarter Earnings Conference Call for 2025 | 2025-08-08T17:00:00 |
| Coherus BioSciences Inc Second Quarter Earnings Results for 2025 | 2025-08-08T00:00:00 |
| Coherus BioSciences Inc Annual General Meeting for 2025 | 2025-05-29T13:30:00 |
| Coherus BioSciences Inc First Quarter Earnings Conference Call for 2025 | 2025-05-09T17:00:00 |
| Coherus BioSciences Inc First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.